Cargando…

Erratum to: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events

Detalles Bibliográficos
Autores principales:	Costabel, Ulrich, Bendstrup, Elisabeth, Cottin, Vincent, Dewint, Pieter, Egan, Jim J. J., Ferguson, James, Groves, Richard, Hellström, Per M., Kreuter, Michael, Maher, Toby M., Molina-Molina, Maria, Nordlind, Klas, Sarafidis, Alexandre, Vancheri, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713954/ http://dx.doi.org/10.1007/s12325-014-0118-8

Ejemplares similares

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
por: Kreuter, Michael, et al.
Publicado: (2021)

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis
por: Molina-Molina, Maria, et al.
Publicado: (2022)

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
por: Maher, Toby M, et al.
Publicado: (2018)

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
por: Molina-Molina, Maria, et al.
Publicado: (2023)

Panel discussion with the experts - Q&A interaction
por: Guichard, Romain, et al.
Publicado: (2022)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Management of central serous chorioretinopathy: Expert panel discussion
por: Chhablani, Jay, et al.
Publicado: (2018)

Breast Implant Illness: An Expert-Panel Discussion on Current Research
por: Kenkel, Jeffrey M, et al.
Publicado: (2021)

Strategies to Reduce Harm: An Expert Panel Discussion on the Fentanyl Crisis
por: Leitz, Sarah J, et al.
Publicado: (2023)

No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis
por: Bendstrup, Elisabeth, et al.
Publicado: (2014)

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
por: Cottin, Vincent, et al.
Publicado: (2018)

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
por: Salih, Goran Nadir, et al.
Publicado: (2016)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion
por: Detiček, Andreja, et al.
Publicado: (2018)

Current role of optical coherence tomography angiography: Expert panel discussion
por: Agarwal, Aniruddha, et al.
Publicado: (2018)

Pirfenidone: an update on clinical trial data and insights from everyday practice
por: Kreuter, Michael
Publicado: (2014)

Burnout and the Effect on the Global Health Care Workforce Crisis: An Expert Panel Discussion
por: Davino-Ramaya, Carrie M, et al.
Publicado: (2023)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

Guideline Adherence of Paediatric Urolithiasis: An EAU Members’ Survey and Expert Panel Roundtable Discussion
por: Bañuelos Marco, Beatriz, et al.
Publicado: (2022)

Competency assessment for community health nurses: a focus group expert panel discussion
por: Kisut, Ramlah, et al.
Publicado: (2022)

Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion
por: Hodak, Emmilia, et al.
Publicado: (2022)

Panel Discussion
por: Prof. DRUKPA, Gyalwang, et al.
Publicado: (2015)

Panel discussion
Publicado: (2006)

Panel discussion
por: Multiple participants
Publicado: (2004)

Panel Discussion
por: CERN. Geneva
Publicado: (2002)

Panel Discussion
por: CERN. Geneva
Publicado: (2018)

Panel discussion
por: Arkani-Hamed, Nima, et al.
Publicado: (2022)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion
por: Hodak, Emmilia, et al.
Publicado: (2023)

Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
por: Maher, Toby M., et al.
Publicado: (2017)

Summary of Panel Discussions
por: Henderson, Rogene F., et al.
Publicado: (1994)

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
por: Valeyre, Dominique, et al.
Publicado: (2014)

Interleukin-2 Expression in Lupoid and Usual Types of Old World Cutaneous Leishmaniasis
por: Mashayekhi Goyonlo, Vahid, et al.
Publicado: (2014)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion
por: Baruchel, André, et al.
Publicado: (2020)

Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
por: Kreuter, Michael, et al.
Publicado: (2023)

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
por: Marijic, Pavo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n9boe8hgq8jqiupat80f5shbik